• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1
CONCLUSION: In HLA-A2 positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to chemotherapy. Further evaluation in this population is warranted.PMID:37704166 | DOI:10.1016/j.annonc.2023.07.006
Source: Ann Oncol - September 13, 2023 Category: Cancer & Oncology Authors: B Besse E Felip R Garcia Campelo M Cobo C Mascaux A Madroszyk F Cappuzzo W Hilgers G Romano F Denis S Viteri D Debieuvre D Galetta E Baldini None M Razaq G Robinet M Maio A Delmonte B Roch P Masson W Schuette A Zer J Remon D Costantini B Vasseur R Dziadzi Source Type: research

Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic
CONCLUSION: Management of patients with mHSPC in Canada has changed during the pandemic, with increased uptake of ARATs and reduced use of docetaxel, a trend expected to continue beyond the pandemic. How this trend will impact uptake of triplet therapy (ADT + ARAT + Docetaxel), downstream treatment choices and overall outcomes remains to be seen.PMID:36621461 | DOI:10.1016/j.clgc.2022.11.020
Source: Clinical Prostate Cancer - January 9, 2023 Category: Cancer & Oncology Authors: Carlos E Stecca Di Maria Jiang Zachary Veitch Sebastian J Hotte Nimira Alimohamed Lori Wood Srikala S Sridhar Source Type: research

Fight Aging! Newsletter, May 2nd 2022
In this study, we tested the therapeutic potential of VHHASC and a newly generated VHH against murine ASC (VHHmASC) to target ASC specks in vitro and in vivo. We show that pre-incubation of extracellular ASC specks with VHHASC abrogated their inflammatory functions in vitro. Recombinant VHHASC rapidly disassembled pre-formed ASC specks and thus inhibited their ability to seed the nucleation of soluble ASC. Notably, VHHASC required prior cytosolic access to prevent inflammasome activation within cells, but it was effective against extracellular ASC specks released following caspase-1-dependent loss of membrane integrity, an...
Source: Fight Aging! - May 1, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Co-infection with Legionella and SARS-CoV-2: a case report
CONCLUSIONS: The patient had a favorable outcome with early diagnosis and early treatment of both diseases. Patients with severe COVID-19 disease need to be evaluated for co-infection. Further, early diagnosis and early treatment of the microbial bacteria causing the co-infection are important.PMID:34409491 | DOI:10.1186/s40981-021-00467-3
Source: Clinical Prostate Cancer - August 19, 2021 Category: Cancer & Oncology Authors: Masaru Shimizu Yusuke Chihara Sakiko Satake Astuko Yone Mari Makio Hideki Kitou Tomohiro Takeda Source Type: research

COVID-19 in a patient receiving adjuvant breast cancer chemotherapy with granulocyte olony-stimulating factor (G-CSF) support: A case report
Mol Clin Oncol. 2021 Jun;14(6):117. doi: 10.3892/mco.2021.2279. Epub 2021 Apr 8.ABSTRACTPatients receiving chemotherapy are at high risk for severe infections and complications such as acute respiratory syndrome. The most commonly used adjuvant chemotherapy protocols (docetaxel-cyclophosphamide every 3 weeks or the dose-dense regimen, doxorubicin-cyclophosphamide every 2 weeks followed by paclitaxel) incorporate granulocyte-colony stimulating factor (G-CSF). G-CSF is routinely administered to prevent chemotherapy-associated neutropenia but often results in significant neutrophilia. The present case describes a patient with...
Source: Clinical Genitourinary Cancer - April 27, 2021 Category: Cancer & Oncology Authors: Rinat Yerushalmi Moshe Sagi Hadar Goldvaser Jonathan Daliot Raz Mutai Ilan Krause Source Type: research

European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo significantly reduces the ti...
Source: Roche Media News - December 23, 2020 Category: Pharmaceuticals Source Type: news